Goldman Sachs Group Inc Surface Oncology, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.61 - $1.03 $275,047 - $464,424	-450,898 Reduced 41.58%	633,569 $443,000
Q1 2023 May 11, 2023	SELL	$0.61 - $1.03 $275,047 - $464,424	-450,898 Reduced 41.58%	633,569 $443,000
Q4 2022 May 14, 2024	SELL	$0.62 - $1.21 $113,943 - $222,373	-183,780 Reduced 14.49%	1,084,467 $889,000
Q4 2022 Feb 13, 2023	SELL	$0.62 - $1.21 $113,943 - $222,373	-183,780 Reduced 14.49%	1,084,467 $889,000
Q3 2022 May 14, 2024	BUY	$1.05 - $2.1 $208,252 - $416,505	198,336 Added 18.54%	1,268,247 $1.32 Million
Q3 2022 Nov 10, 2022	BUY	$1.05 - $2.1 $208,252 - $416,505	198,336 Added 18.54%	1,268,247 $0
Q2 2022 May 14, 2024	BUY	$1.42 - $3.15 $1.52 Million - $3.37 Million	1,069,911 New	1,069,911 $1.76 Million
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $305,743 - $678,232	215,312 Added 25.19%	1,069,911 $1.76 Million
Q1 2022 May 16, 2022	BUY	$2.65 - $5.08 $373,597 - $716,178	140,980 Added 19.76%	854,599 $2.51 Million
Q4 2021 Feb 14, 2022	SELL	$4.73 - $7.9 $2.3 Million - $3.84 Million	-486,270 Reduced 40.53%	713,619 $3.41 Million
Q3 2021 Nov 10, 2021	BUY	$5.16 - $7.98 $6.19 Million - $9.58 Million	1,199,889 New	1,199,889 $9.08 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.